Express Scripts: Pricey PCSK9 drugs poised to ‘wreak havoc’

Carly Helfand Last week, Sanofi revealed a $ 14,600 sticker for new PCSK9 med Praluent that far exceeded the price tag analysts expected. And unsurprisingly, leading ...

UPDATED: Allergan bags NMDA depression drugs in $560M-plus Naurex buyout

John Carroll The big news in biopharma this weekend is the unconfirmed report that Allergan is looking to sell its generics business to Teva. But Allergan execs didn't let the headlines ...

Neos pulls off a $72M IPO to push its ADHD drugs forward

Damian Garde Texas biotech Neos Therapeutics cleared $ 72 million in an IPO, raising cash to develop some reformulated takes on existing drugs for ADHD. FierceBiotech News

Big Pharma pushes new migraine drugs into Phase III with blockbuster hopes

Damian Garde A cadre of drugmakers is pressing toward late-stage trials with new injectable treatments in the long-stagnant field of migraine therapy, racing to capitalize on what analysts ...

With vet drugs pumping, it’s no wonder that pharma’s eyeing M&A

Carly Helfand What's with all the M&A rumors floating around in the animal health world? Just look at Zoetis' Apoquel and it's clear why Big Pharma names are keen ...

UPDATED: Celgene pays $1B in landmark deal to buy into Juno’s pipeline of CAR-T drugs

John Carroll Celgene is paying about $ 1 billion to move to the front of the hectic race to build new CAR-T cancer therapies. The Big Biotech is shelling out $ 150 million upfront ...

Alexion wins EMA nods for not one but two drugs

Eric Palmer Rare-disease specialist Alexion Pharmaceuticals won a double header from the EMA today when the agency recommended approval of two of its drugs, including Kanuma, the enzyme ...

Merck cancer drugs and Sanofi, Amgen cardio meds have formularies on high alert

Eric Palmer U.S. drug payers have been able to beat back high prices for some COPD and diabetes drugs, much to the chagrin of GlaxoSmithKline and Sanofi. But several new categories ...

Alexion gets EU green light for a pair of rare disease drugs

Damian Garde European regulators are recommending approval for two rare disease treatments from Alexion, a victory for the biotech as it works to expand its stable of commercialized ...

Caforio takes CEO role as BMS faces tough year with promising new drugs

Eric Palmer Trained in his native Italy as a doctor, Giovanni Caforio speaks not only English and Italian, but also Spanish, French and Portuguese. As he steps into the CEO role today ...

Small group of branded drugs like Nexium, Copaxone make up huge part of Medicare spend

Eric Palmer It's a good thing for Medicare that AstraZeneca's Nexium has gone generic and Teva's Copaxone is headed that way. That is because they are among about 10% of ...

EMA, like FDA, says testosterone-raising drugs are not for lifestyle use

Eric Palmer The European Medicines Agency has thrown more cold water on sales of testosterone-raising meds as a party drug for aging men. The agency said today that the evidence is ...
Page 2 of 1212345...10...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS